Biomarkers in atrial fibrillation.
Research type
Research Study
Full title
Discovering novel biomarkers in patients with atrial fibrillation.
IRAS ID
239846
Contact name
Svetlana Reilly
Contact email
Sponsor organisation
University of Oxford / Clinical Trials and Research Governance
Duration of Study in the UK
1 years, 10 months, 0 days
Research summary
The purpose of this study is to investigate the link between inflammation (an important process in heart diseases) and atrial fibrillation (a very common rhythm disorder).
We are going to recruit up to 360 patients undergoing procedure of ablation (up to 160 patients) or cardioversion (up to 200 patients) in the John Radcliffe hospital in Oxford. Both procedures are commonly used in treatment of atrial fibrillation. This study is a lab-based observational study which will involve analysing of the peripheral and intra-cardiac (for the ablation cohort only) blood samples collected before and after the procedures.
Participants will have 4 research visit for the Ablation cohort and 2 research visit for the Cardioversion cohort.
The blood samples will be assessed for new biomarkers (e.g., inflammatory)which may change after the procedure of ablation or cardioversion. We will then test if these markers will be associated with the recurrence of atrial fibrillation after the procedures. The study is funded by the BHF.REC name
South Central - Berkshire B Research Ethics Committee
REC reference
18/SC/0304
Date of REC Opinion
18 Jun 2018
REC opinion
Favourable Opinion